BioCatalyst

EXEL — EXELIXIS, INC. catalysts

1 verified catalyst event(s) for EXELIXIS, INC. (ticker EXEL). Each is linked to its official source. Verified as of 2026-08-06.

Next verified catalyst

2026-12-15 — Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear · official source ↗

Upcoming

DateEventCompanyDrugOfficial source & verification
2026-12-15
in 4mo
ESTIMATED
 READOUT
Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic
Phase 3 · Non-Clear Cell Renal Cell Carcinoma
 EXEL EXELIXIS, INC. XL092, Nivolumab, Sunitinib Malate ClinicalTrials.gov ↗
✓ Source-checked 2026-08-06
Sponsor-projected date — can change
Disclaimer. Bio Catalyst Calendar is a public-events data calendar. Every date is sourced and linked to an official record (ClinicalTrials.gov, FDA / Federal Register, openFDA). It is scheduling and reference data only — NOT investment advice, a recommendation, or a buy/sell signal. Dates set by sponsors and the FDA can change; always confirm against the linked official source.